Efficacy and safety of switching between biologics in chronic rhinosinusitis with nasal polyps or N-ERD
Rhinology Journal · 2023
DOI: 10.4193/rhin22.408 ↗Kurz gefasst
Fachartikel in der Zeitschrift Rhinology Journal, 2023. Verfasst von F F Brkic und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, General Hospital and Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Biological Products, Nasal Polyps, Sinusitis, Asthma. Die Arbeit wurde bisher 19-mal zitiert (Crossref).
Abstract (Originalsprache)
Background and objective: The effectiveness of biologics in chronic rhinosinusitis with nasal polyps (CRSwNP) is well-establis- hed. However, real-world experience on the effectiveness of transitioning between two monoclonal antibodies is scarce. There- fore, we aimed to analyze the safety and efficacy of antibody switching in treatment of chronic rhinosinusitis.
Methods
All patients with CRSwNP or nonsteroidal anti-inflammatory drugs-exacerbated respiratory disease (N-ERD) requiring a switch between biologics were retrospectively studied. Analysis included changes in polyp size, quality of life parameters, asthma control, and side effects.
Results
Out of 195 patients treated with biologics for CRSwNP or N-ERD in our center, 23 (11.8%) required transition to a different monoclonal antibody. The majority switched from omalizumab to dupilumab (17/23, 73.9%), mostly due to inadequate symptom control. Nine out of these 17 patients (52.9%) were switched without a washout period. All patients showed significant improve- ment in nasal polyp score, asthma control test and sino-nasal outcome test-22 after changing to dupilumab. Keratoconjunctivitis sicca was the side-effect (4.3%) reported after the switch from omalizumab to dupilumab, which lead to termination of therapy in one patient. Due to limited sample size, other antibody transitions were reported in a descriptive manner.
Conclusion
The transition to dupilumab is an effective option in patients with inadequate treatment response or side-effects of omalizumab in nasal polyposis. Our preliminary results indicate that a wash-out period may not be necessary when switching between biologics, however, these findings require further investigations. Other monoclonal antibody transitions also show pro- mising results, but warrant validations in larger cohorts due to small patient samples in our study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, General Hospital and Medical University of Vienna, Vienna, Austria.
- Department of Dermatology, General Hospital and Medical University of Vienna, Vienna, Austria.
Zitieren
APA
Brkic, F. F., Liu, D. T., Klimbacher, R., Campion, N. J., Bartosik, T. J., Vyskocil, E., Stanek, V., Tu, A., Arnoldner, T., Bangert, C., Gangl, K., Eckl-Dorna, J., & Schneider, S. (2023). Efficacy and safety of switching between biologics in chronic rhinosinusitis with nasal polyps or N-ERD. Rhinology Journal. https://doi.org/10.4193/rhin22.408
Vancouver
Brkic FF, Liu DT, Klimbacher R, Campion NJ, Bartosik TJ, Vyskocil E, et al. Efficacy and safety of switching between biologics in chronic rhinosinusitis with nasal polyps or N-ERD. Rhinology Journal. 2023. doi:10.4193/rhin22.408
BibTeX
@article{Brkic2023,
author = {Brkic, F F and Liu, D T and Klimbacher, R and Campion, N J and Bartosik, T J and Vyskocil, E and Stanek, V and Tu, A and Arnoldner, T and Bangert, C and Gangl, K and Eckl-Dorna, J and Schneider, S},
title = {Efficacy and safety of switching between biologics in chronic rhinosinusitis with nasal polyps or N-ERD},
journal = {Rhinology Journal},
year = {2023},
doi = {10.4193/rhin22.408}
}
EUVIMED